# US 2021/0171528 A1 · Dopamine-b-hydroxylase inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0171528 A1
- Document ID: US20210171528A1
- Status: Published application
- Kind: A1
- Application number: 16/769,045
- Filed: 2018-11-30
- Published: 2021-06-10
- Earliest claimed: 2017-12-04
- Assignees: Bial - Portela & Ca, S.A.
- Applicants: Bial - Portela & Cª, S.A.
- Inventors: Laszlo Erno Kiss; Alexander Beliaev; Tino Rossi; Pedro Nuno Leal Palma; Patrício Manuel Vieira Araujo Soares Da Silva; Rui Pinto; Francisco Cardona
- Web page: https://patentgrep.com/patent/US20210171528A1

## CPC

- C07D 487/04: Ortho-condensed systems
- C07D 487/14: Ortho-condensed systems
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/12: Antihypertensives
- A61P 19/10: for osteoporosis
- A61P 25/00: Drugs for disorders of the nervous system
- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C07B 2200/05: Isotopically modified compounds, e.g. labelled
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

This invention relates to: (a) compounds of formula Ia (with R1, R4 to R6, n and A as defined herein) and pharmaceutically acceptable salts or solvates thereof that are useful as dopamine-β-hydroxylase inhibitors; (b) pharmaceutical compositions (comprising such compounds, salts or solvates; (c) the use of such compounds, salts or solvates in therapy; (d) therapeutic methods of treatment using such compounds, salts or solvates; and (e) processes and intermediates useful for the synthesis of such compounds.

## Claims

### Claim 1

(canceled)

### Claim 2

A compound of formula Ia, or a pharmaceutically acceptable salt or solvate thereof:
wherein:
R1 is hydrogen, C1-C6 alkyl, partially or fully deuterated C1-C6 alkyl or C3-C6 cycloalkyl;
R4 is hydrogen or C1-C3 alkyl;
R5 is hydrogen;
or R4 and R combine, together with the carbon atoms to which they are attached, to form a cyclopropyl ring;
R6 is —COOH, —CHO, or —(CH2)m—X,
wherein:
m is 1, 2 or 3 and one —CH2— moiety within —(CH2)m— may optionally be replaced by
X is hydroxy, C1-C3 alkoxy, cyano, —N═CH(NHCN)(NH2), —NH—C(pyrrolidin-1-yl)=NCN, 5- or 6-membered heteroaryl optionally substituted with one methyl group, phenyl, —SO2—R7, —NR8R9, —CO2R10, —CH(CO2R10)2, —CONR11R12 or —NR13COR14;
wherein:
R7 is C1-C3 alkyl;
R8 is hydrogen or C1-C3 alkyl;
R9 is hydrogen,
C1-C4 alkyl optionally substituted with up to three fluoro substituents or with one substituent selected from the group consisting of hydroxy, methylsulfonyl, C3-C6 cycloalkyl, phenyl, 5- or 6-membered heterocyclyl and 5- or 6-membered heteroaryl optionally substituted with one methyl substituent,
C3-C6 cycloalkyl,
5- or 6-membered heteroaryl, or
5- or 6-membered heterocyclyl optionally substituted with one or two oxo substituents;
or R8 and R9 combine together with the N atom to which they are attached to form a 5- or 6-membered N-heterocyclyl group optionally substituted with one substituent selected from methyl, trifluoromethyl, hydroxy, hydroxymethyl, methoxymethyl, methylsulfonyl, amido, (N,N-dimethyl)acetamide and pyridyl or with one or two substituents selected from fluoro and oxo, or a 9- or 10-membered heterospirocyclyl group;
R10 is hydrogen or C1-C3 alkyl;
R1 is hydrogen or C1-C3 alkyl;
R12 is hydrogen,
C1-C4 alkyl optionally substituted with up to three fluoro substituents or with one substituent selected from the group consisting of cyano, hydroxy, methylsulfonyl, C1-C2 alkoxy, dimethylamino, C3-C6 cycloalkyl, phenyl, 5- or 6-membered heteroaryl optionally substituted with one methyl substituent and 5- or 6-membered heterocyclyl optionally substituted with one t-Boc group or with one or two fluoro substituents,
C3-C6 cycloalkyl optionally substituted with one substituent selected from the group consisting of cyano, hydroxy, hydroxymethyl and oxo,
cyano,
methylsulfonyl,
CH2COO(C1-C3 alkyl),
5- or 6-membered heteroaryl optionally substituted with one methyl substituent,
4-, 5- or 6-membered heterocyclyl optionally substituted with one or two substituents selected from oxo and methyl,
CH2CH(NH2)(COOH), or
CH(CH3)CONH2;
or R1 and R12 combine together with the N atom to which they are attached to form a 5- or 6-membered N-heterocyclyl group optionally substituted with one substituent selected from monofluromethyl, trifluoromethyl, hydroxy, hydroxymethyl, methoxymethyl, methylsulfonyl, cyano, amido, (N,N-dimethyl)acetamide and pyridyl, or with one or two substituents selected from fluoro, methyl and oxo, or optionally fused to a cyclopropyl ring which may be substituted with one or two methyl substituents, or a 9- or 10-membered heterospirocyclyl group;
R13 is hydrogen or C1-C3 alkyl;
R14 is C1-C4 alkyl optionally substituted with up to three fluoro substituents or with one substituent selected from the group consisting of hydroxy, methylsulfonyl, C3-C6 cycloalkyl and phenyl,
C3-C6 cycloalkyl,
5- or 6-membered heteroaryl, or
5- or 6-membered heterocyclyl optionally substituted with one or two oxo substituents;
A is C5-C7 cycloalkyl, furanyl, thiophenyl, methylthiophenyl or
wherein:
X1 is hydrogen, halo or methyl;
X1′ is hydrogen or halo;
X2 is hydrogen, halo or methyl;
X2′ is hydrogen or halo;
X3 is hydrogen or fluoro;
n is 0 or 1, and when n is 0 a single bond joins the carbon atoms to which the CH2 moiety would be attached when n is 1.

### Claim 3 (depends on 2)

A compound according to claim 2, wherein n is 0.

### Claim 4 (depends on 2)

A compound according to claim 2, wherein R4 and R5 combine, together with the carbon atom to which they are attached, to form a cyclopropyl ring.

### Claim 5 (depends on 2)

A compound according to claim 2, wherein more than 50% of substituents R5 and A have the stereochemical configuration of formula Id

### Claim 6 (depends on 2)

A compound according to claim 2, wherein more than 50% of substituents R5 and A have the stereochemical configuration of formula Ie

### Claim 7 (depends on 1, 2)

A compound according to claim 2, wherein A is
wherein X1, X1′, X2, X2′ and X3 are as defined in claim 1.

### Claim 8 (depends on 2)

A compound according to claim 2, wherein R1 is hydrogen, methyl or d3-methyl.

### Claim 9 (depends on 2)

A compound according to claim 2, wherein R4 is hydrogen or methyl.

### Claim 10 (depends on 2)

A compound according to claim 2, wherein R5 is hydrogen.

### Claim 11 (depends on 2)

A a compound according to claim 2, wherein R6 is —COOH, —CHO, or —(CH2)m—X,
wherein:
m is 1, 2 or 3 and one —CH2— moiety within —(CH2)m— may optionally be replaced by
X is hydroxy, ethoxy, cyano, —N═C(NHCN)(NH2), —NH—C(pyrrolidin-1-yl)=NCN, 1-methylimidazol-2-yl, 3-methyl-1,2,4-oxadiazol-5-yl, tetrazol-5-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, phenyl,
—SO2—R7, —NR8R9, —COOR10, —CH(COOR10)2, —CONR11R12 or —NR13COR14;
wherein:
R7 is methyl;
R8 is hydrogen or methyl;
R9 is hydrogen, methyl, cyclopropylmethyl, benzyl, 2-hydroxyethyl, 2,2,2-trifluoroethyl, 2-methylsulfonylethyl, 1-cyclohexylethyl, isopropyl, butyl, cyclopropyl, cyclobutyl, cyclopentyl, tetrahydrofuran-3-yl, (tetrahydrofuran-2-yl)methyl, (1,1-dioxido)tetrahydrothiopyran-4-yl, (tetrahydro-2H-pyran-4-yl)methyl, pyridin-2-yl, pyridin-3-yl, tetrahydropyran-3-yl, cyclohexyl, (pyridin-2-yl)methyl or (1-methylpyrazol-4-yl)methyl;
or R8 and R9 combine together with the N atom to which they are attached to form a pyrrolidinyl, piperidinyl, 4-methylsulfonyl-piperidinyl, 4,4-difluoro-piperidinyl or morpholinyl group;
R10 is hydrogen, methyl or ethyl;
R11 is hydrogen or methyl;
R12 is hydrogen, methyl, cyanomethyl, cyclopropylmethyl, benzyl, (pyridin-2-yl)methyl, (pyridin-3-yl)methyl, (N-t-Boc-pyrrolidin-2-yl)methyl, 2-hydroxyethyl, 2-methoxyethyl, 2,2,2-trifluoroethyl, 2-methylsulfonylethyl, 1-cyclohexylethyl, 2-(pyridin-2-yl)ethyl, 2-(1H-pyrazol-1-yl)ethyl, 2-(4,4-difluoropiperidin-1-yl)ethyl, propyl, isopropyl, 3-(N,N-dimethylamino)propyl, 3-(morpholin-1-yl)propyl, butyl, cyclopropyl, 1-cyanocyclopropyl, cyclobutyl, cyclopentyl, 2-hydroxycyclopentyl, 2-hydroxymethylcyclopentyl, 2-oxocyclopentyl, cyclohexyl, 2-hydroxycyclohexyl, 4-hydroxycyclohexyl, cyano, methylsulfonyl, CH2COOEt, tetrahydrofuran-3-yl, 2-oxotetrahydrofuran-3-yl, tetrahydropyran-3-yl, tetrahydropyran-4-yl, (1,1-dioxido)tetrahydrothiopyran-4-yl, 1,3,4-thiadiazol-2-yl, pyridin-2-yl, pyridin-3-yl, CH2CH(NH2)(COOH), CH(CH3)CONH2, oxazol-2-yl, (pyrazine-2-yl)methyl, oxetan-3-yl, (tetrahydrofuran-2-yl)methyl, (1-methylpyrazol-4-yl)methyl, thiazol-2-yl, 2-oxopyrrolidin-3-yl, 2-cyanocyclopentyl, isoxazol-4-yl, 3-methyl-1,2,4-oxadiazol-5-yl, (tetrahydropyran-4-yl)methyl, 2-oxopiperidin-3-yl, 1-methylpyrazol-4-yl, isothiazol-4-yl, 1-methyl-2-oxopiperidin-5-yl, 1-methyl-2-oxopyrrolidin-3-yl, 1-methyl-5-oxopyrrolidin-3-yl or 1-methyl-2-oxopyrrolidin-4-yl;
or R11 and R12 combine together with the N atom to which they are attached to form a pyrrolidinyl, 2-hydroxymethyl-pyrrolidinyl, 2-methoxymethyl-pyrrolidinyl, 2-trifluoromethyl-pyrrolidinyl, 3-(fluoromethyl)pyrrolidinyl, 3-methylsulfonyl-pyrrolidinyl, N,N-dimethylpyrrolidinyl-3-carboxamide, piperidinyl, 3-hydroxy-piperidinyl, 4-hydroxy-piperidinyl, 4-methyl-piperidinyl, 4-hydroxymethyl-piperidinyl, 4-amido-piperidinyl, 4-methylsulfonyl-piperidinyl, 4,4-difluoro-piperidinyl, N,N-dimethylpiperidinyl-4-carboxamide, N4-methyl-piperazinyl, N4-(N,N-dimethyl)acetamide-piperazinyl, N4-(pyridine-2-yl)piperazinyl, morpholinyl, thiomorpholinyl, 1-oxidothiomorpholinyl, 1,1-dioxidothiomorpholinyl, 2-oxa-7-azaspiro[4.4]nonanyl, 2-oxa-8-azaspiro[4.5]decanyl, 1,4-dioxa-8-azaspiro[4.5]decanyl group, 6,6-dimethyl-3-azabicyclo[3.1.0]hexanyl, piperazinyl, 3-oxopiperazinyl, 4-methyl-3-oxopiperazinyl, 2-cyanopyrrolidinyl, 3-cyanopyrrolidinyl, 3-fluoromethylpyrrolidinyl or 3-(N,N-dimethylacetamide)pyrrolidinyl;
R13 is hydrogen or methyl;
R14 is cyclopropyl, cyclopentyl, pyrrolidin-1-yl, tetrahydropyran-4-yl or pyridin-3-yl.

### Claim 12 (depends on 2)

A compound according to claim 2, wherein A is
DN,
wherein:
X1 is hydrogen, fluoro, chloro or methyl;
X1′ is hydrogen, fluoro or chloro;
X2 is hydrogen, fluoro, chloro, bromo or methyl;
X2′ is hydrogen, fluoro, chloro or bromo;
X3 is hydrogen or fluoro.

### Claim at position 13

13-14. (canceled)

### Claim 15 (depends on 2)

A method for treating or preventing conditions ameliorated by inhibition of dopamine-beta-hydroxylase outside the central nervous system comprising administering a therapeutically effective amount of a compound of formula Ia, as defined in claim 2, or a pharmaceutically acceptable salt or solvate thereof, to a patient in need thereof.

### Claim 16 (depends on 2)

A pharmaceutical composition comprising (i) a therapeutically effective amount of a compound of formula Ia, as defined in claim 2, or a pharmaceutically acceptable salt or solvate thereof, and (ii) a pharmaceutically acceptable excipient.

### Claim 17 (depends on 2)

A compound of formula Ia, as defined in claim 2, or a pharmaceutically acceptable salt or solvate thereof, with the proviso that the compound (S)-1-benzyl-6-(3,5-difluorophenyl)-6,7-dihydro-2H-pyrrolo[1,2-c]imidazole-3(5H)-thione is excluded.
